Aethlon Medical announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with prior observations. This update provides incremental positive data for their ongoing study, with full statistical analysis pending completion of all cohorts.
Aethlon Medical (AEMD) reported that the second cohort of its Australian oncology feasibility study showed biological changes consistent with previously reported observations. This is a positive, albeit incremental, update for the company as it progresses through its clinical trials. While not a definitive outcome, it suggests the therapy is having an intended biological effect, which is crucial for further development. The market impact is likely moderate in the short term, as the full statistical analysis is still pending. Long-term implications depend on the final study results, which could significantly impact AEMD's valuation if positive. Traders should note this as a step forward, but await more comprehensive data for a clearer picture of the drug's efficacy.